PE20160507A1 - Diferenciacion de celulas madre mesenquimales - Google Patents

Diferenciacion de celulas madre mesenquimales

Info

Publication number
PE20160507A1
PE20160507A1 PE2015002636A PE2015002636A PE20160507A1 PE 20160507 A1 PE20160507 A1 PE 20160507A1 PE 2015002636 A PE2015002636 A PE 2015002636A PE 2015002636 A PE2015002636 A PE 2015002636A PE 20160507 A1 PE20160507 A1 PE 20160507A1
Authority
PE
Peru
Prior art keywords
differentiation
stem cells
mesenchymal stem
peptide
fibrinogenic
Prior art date
Application number
PE2015002636A
Other languages
English (en)
Inventor
Lori Jennings
Peter G Schultz
Kristen Johnson
Original Assignee
Scripps Research Inst
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Irm Llc filed Critical Scripps Research Inst
Publication of PE20160507A1 publication Critical patent/PE20160507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Abstract

Referida a una composicion que comprende un polipeptido que consiste en un peptido ANGPTL3 C-terminal de dominio fibrinogeno que comprende una secuencia de aminoacidos seleccionada entre cualquiera de las SEC ID NO: 1, 2, 3, 25, 26 o 27, en donde dicho peptido tiene actividad condrogenica. Estas composiciones se emplean para mejorar o prevenir la artritis o lesiones articulares en un mamifero
PE2015002636A 2009-07-14 2010-07-13 Diferenciacion de celulas madre mesenquimales PE20160507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
PE20160507A1 true PE20160507A1 (es) 2016-05-20

Family

ID=43450138

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000052A PE20120570A1 (es) 2009-07-14 2010-07-13 Diferenciacion de celulas madre mesenquimales
PE2015002636A PE20160507A1 (es) 2009-07-14 2010-07-13 Diferenciacion de celulas madre mesenquimales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000052A PE20120570A1 (es) 2009-07-14 2010-07-13 Diferenciacion de celulas madre mesenquimales

Country Status (31)

Country Link
US (4) US9139633B2 (es)
EP (1) EP2453921B1 (es)
JP (1) JP5602850B2 (es)
KR (3) KR20160015403A (es)
CN (2) CN105601728B (es)
AU (1) AU2010273570B2 (es)
BR (1) BR112012000914B8 (es)
CA (1) CA2767826C (es)
CL (1) CL2012000091A1 (es)
CO (1) CO6491059A2 (es)
CR (1) CR20120024A (es)
CU (1) CU24042B1 (es)
EA (1) EA023073B1 (es)
EC (1) ECSP12011604A (es)
ES (1) ES2541217T3 (es)
GT (1) GT201200011A (es)
HK (1) HK1164169A1 (es)
IL (2) IL217383A (es)
IN (1) IN2012DN00572A (es)
MA (1) MA33423B1 (es)
MX (1) MX2012000707A (es)
MY (1) MY160951A (es)
NZ (1) NZ597306A (es)
PE (2) PE20120570A1 (es)
PL (1) PL2453921T3 (es)
PT (1) PT2453921E (es)
SG (1) SG177318A1 (es)
TN (1) TN2011000655A1 (es)
UA (1) UA104031C2 (es)
WO (1) WO2011008773A2 (es)
ZA (1) ZA201200078B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN110198450B (zh) 2011-11-08 2021-12-31 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
JP5918909B2 (ja) 2012-06-25 2016-05-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CN105228626A (zh) 2013-03-15 2016-01-06 加州生物医学研究所 用于诱导软骨形成的化合物和方法
UY36118A (es) 2014-05-13 2016-01-08 Novartis Ag Compuestos y composiciones para inducir condrogénesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
MX2019005621A (es) * 2016-11-14 2019-08-12 Novartis Ag Metodos y composiciones para el tratamiento del daño del cartilago y la artritis.
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US20220071972A1 (en) 2018-12-06 2022-03-10 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736A (zh) * 2018-12-06 2021-06-22 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1159419A1 (en) 1999-03-08 2001-12-05 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2291198T3 (es) 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
WO2002033085A2 (en) * 2000-10-16 2002-04-25 Genentech, Inc. Wisp polypeptides and therapeutical applications thereof
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
NZ532852A (en) * 2001-11-16 2006-08-31 Genentech Inc Composition comprising and method of using angiopoietin-like protein 3 Angptl3
CA2498167C (en) * 2002-09-09 2012-03-20 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
CN1761749A (zh) * 2003-03-10 2006-04-19 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
WO2006002152A1 (en) * 2004-06-21 2006-01-05 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
US8609411B2 (en) 2007-05-04 2013-12-17 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular

Also Published As

Publication number Publication date
SG177318A1 (en) 2012-03-29
MA33423B1 (fr) 2012-07-03
IL217383A0 (en) 2012-02-29
AU2010273570B2 (en) 2014-07-03
CN102625830B (zh) 2016-03-02
ECSP12011604A (es) 2012-06-29
AU2010273570A1 (en) 2012-02-02
KR20120029472A (ko) 2012-03-26
IN2012DN00572A (es) 2015-06-12
CU24042B1 (es) 2014-11-27
KR101590834B1 (ko) 2016-02-12
US10555990B2 (en) 2020-02-11
CO6491059A2 (es) 2012-07-31
CA2767826A1 (en) 2011-01-20
EP2453921A4 (en) 2012-12-19
BR112012000914B1 (pt) 2021-04-06
HK1164169A1 (en) 2012-09-21
CN105601728B (zh) 2020-01-10
ES2541217T3 (es) 2015-07-16
CA2767826C (en) 2015-11-24
CL2012000091A1 (es) 2012-10-26
BR112012000914A8 (pt) 2017-12-19
US20200108122A1 (en) 2020-04-09
US10064918B2 (en) 2018-09-04
GT201200011A (es) 2013-12-10
UA104031C2 (uk) 2013-12-25
US20190000922A1 (en) 2019-01-03
KR20160015403A (ko) 2016-02-12
KR20180000337A (ko) 2018-01-02
EA201200118A1 (ru) 2012-09-28
US20120177644A1 (en) 2012-07-12
EA023073B1 (ru) 2016-04-29
CN102625830A (zh) 2012-08-01
WO2011008773A2 (en) 2011-01-20
PE20120570A1 (es) 2012-05-19
IL217383A (en) 2016-08-31
US20160213748A1 (en) 2016-07-28
NZ597306A (en) 2014-03-28
US11241482B2 (en) 2022-02-08
JP2012533549A (ja) 2012-12-27
TN2011000655A1 (en) 2013-05-24
PT2453921E (pt) 2015-09-25
JP5602850B2 (ja) 2014-10-08
PL2453921T3 (pl) 2015-11-30
EP2453921B1 (en) 2015-05-27
EP2453921A2 (en) 2012-05-23
CU20120007A7 (es) 2013-02-26
WO2011008773A3 (en) 2011-08-25
MY160951A (en) 2017-03-31
IL247310B (en) 2018-04-30
BR112012000914B8 (pt) 2021-05-25
US9139633B2 (en) 2015-09-22
CR20120024A (es) 2012-06-11
CN105601728A (zh) 2016-05-25
MX2012000707A (es) 2012-03-21
BR112012000914A2 (pt) 2017-08-08
ZA201200078B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
AR110834A2 (es) MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal)
AR086214A1 (es) Composiciones detergentes que contienen mananasa de bacillus agaradhaerens y sus metodos de uso
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
NZ607069A (en) Modified relaxin polypeptides and their uses
NZ606584A (en) Binding proteins for hepcidin
AR086215A1 (es) Composiciones detergentes que contienen mananasa de geobacillus tepidamans y metodos de uso de las mismas
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
NZ600690A (en) Fkbp-l and uses thereof
PE20081140A1 (es) Agentes terapeuticos a base de peptidos derivados de toxinas
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
EA201300060A1 (ru) Полипептид, обладающий или содействующий активности деградации углеводного материала, и его применение
ES2691539T3 (es) Luciferasas de Oplophorus sintéticas con mayor emisión de luz
NZ707439A (en) Modified factor ix polypeptides and uses thereof
PE20120914A1 (es) Compuestos glucagon activo de receptor de gip
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
ECSP099276A (es) Agente para prevenir/tratar el cancer
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
IN2012DN00801A (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed